Zelira Therapeutics (AU:ZLD) has released an update.
Zelira Therapeutics has secured a $1.4 million unsecured loan from its Chairman Osagie Imasogie, intended to advance the HOPE SPV clinical trial and for general working capital. The loan could convert to shares at $0.40, a significant premium over the recent closing price, pending shareholder approval at the upcoming AGM. This strategic financial move is aimed at bolstering the company’s efforts in clinically validated cannabis medicines and other proprietary revenue-generating products.
For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.
